To evaluate the efficacy and safety of ramucirumab ( IMC-@B ; LY@ ) , a fully human monoclonal antibody targeting the vascular endothelial growth factor receptor-@ , alone and in combination with dacarbazine in chemotherapy-nave patients with metastatic melanoma ( MM ) .